Ptc Therapeutics, Inc. (PTCT) Stock Price & Analysis

Ptc Therapeutics, Inc. (PTCT) fell 2.94% to USD 69.3 as of September 8, 2026 at 05:00 UTC, according to Nexqual real-time market data.

PTCT last closed at USD 69.3; the session ranged USD 69.26–71.41 on volume of 673,539 shares. Market capitalization is —, with a 52-week range of USD 56.95–90.87 (NMS). Source: Nexqual, September 8, 2026 at 05:00 UTC.

Key Statistics (as of September 8, 2026 at 05:00 UTC)

Technical Analysis (PTCT)

Nexqual's technical model rates PTCT "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:00 UTC.

From Ptc Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• The patent portfolio includes patents and patent applications with claims including composition of matter, pharmaceutical formulation and methods of use of our commercial products including sepiapterin, the active ingredient in the formulated product Sephience, ataluren, the active ingredient in the formulated product Translarna, and risdiplam, the active ingredient in the formulated product Evrysdi.
• We seek to protect our proprietary technology and processes, in part, using confidentiality agreements with our employees, consultants, scientific advisors, contractors and collaborators.
• Intellectual Property Patents and trade secrets Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
• We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.

Partnerships

• In addition, Akcea has granted to us a non-exclusive right and license, with the right to grant certain sublicenses, under Akcea's core intellectual property and manufacturing intellectual property to develop, manufacture and commercialize the Products in the PTC Territory and to manufacture the Products worldwide in accordance with a supply agreement with Akcea.
• In November 2024, we entered into a License and Collaboration Agreement with Novartis Pharmaceuticals Corporation, or Novartis, relating to our votoplam program, or the Novartis Agreement, which included related molecules.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:00 UTC. This page is informational and not investment advice.